Mean change in HbA_1c [%] -0,37% -0,42% -1,53% -0,22% -0,42% -1,67% -2,00% -1,00% 0,00% type 1 type 2 basal-bolus type 2 insulin+OAD IDet NPH Mean change in BMI [kg/m2] -0,2 0,26 0,42 0,06 0,51 0,99 type 1 type 2 basal- bolus type 2 insulin+OAD IDet NPH Non-specific mortality No Yes No Yes Laser treatment ACEI treatment Statin treatment Aspirin treatment User sets simulation conditions Generate baseline population Any patients to run? Time horizon reached? Stop Screening Overall annual survival Time counter advances Update simulation data ACEI – Angiotensin converting enzyme inhibitor Microvascular complications Macrovascular complications Walczak J. , Pawlik D. , Jasińska A. , Garbacka M.. , Kędzior J. , Fundament T. , Malczak I. , Dardziński W. , Nogas G. , Skrzekowska-Baran I. , Czech M. Arcana Institute, Cracow, Poland, Novo Nordisk Pharma Poland, Warsaw, Poland 1 1 1 1 1 1 1 1 1 2 2 1 2 Insulin detemir Packet Public selling price (VAT included) [PLN] Reimbursement [PLN] Patient’s co- payment [PLN] Reimbursement per 1 i.u. [PLN] Levemir 5 wkl. 3ml 271,01 267,81 3,20 0,18 Type 1 and type 2 diabetes patients treated with IIT Proportion of patients with episodes of severe hypoglycaemia * Proportion of patients treated with IIT, receiving NPH insulin Target population 65 800 0,089 95% 65 800 × 95% × 8,9% = about 5,6 thousand patients Total annual cost [PLN] IDet NPH Type 1 diabetes Insulin detemir/NPH 1 903,74 792,82 Short-/ rapid-acting insulin 828,42 592,85 Total 2 732,16 1 385,67 Type 2 diabetes (intensive insulin therapy) Insulin detemir/NPH 2 662,87 1 005,92 Total 3 988,56 1 788,05 Type 2 diabetes (insulin + oral antidiabetes drugs) Insulin detemir/NPH 3 303,17 1 114,11 Oral antidiabetes drugs 327,38 327,38 Total 3 630,55 1 441,49